You are here
Articles on Targeted Therapy in Gastric Cancer
This section of the Advances in Gastrointestinal Cancer Resource Centre focuses on the latest clinically relevant findings in targeted therapy for gastrointestinal cancers. The peer-reviewed articles available here have been independently selected, and several commented upon, by members of the Editorial Board. Many of the articles are freely available for downloading.
Focusing initially on gastric cancer, these pages will provide new content each month to help you stay abreast of recent scientific developments in this area.
Exciting findings from genomic sequencing have opened up the therapeutic possibilities for gastric cancer, particularly that in advanced stages, and made targeted therapy possible. Molecular signatures that appear to be associated with a poor prognosis or aggressive disease and may be amenable to targeting in gastric cancer include HER-2, EGFR, VEGF, HGF and the MET pathway, and mTOR.1
Targeted therapies already approved in the USA and Europe for use in gastric cancer include trastuzumab (which targets HER-2) and ramucirumab (which targets VEGF). Many others have been or continue to be under study in clinical trials, including the HER-2 inhibitors lapatinib and pertuzumab, the EGFR inhibitor panitumumab, the VEGF inhibitors apatinib and aflibercept. Much of the research in this area is examining combinations of these targeted agents with each other or with chemotherapy.
To stay abreast of the most recent developments and clinical trial findings in the use of targeted therapy for the treatment of gastrointestinal cancers, please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor 2; HGF, hepatocyte growth factor; mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor.
1. Qiu M-Z, Xu R-H. The progress of targeted therapy in advanced gastric cancer. Biomarker Res. 2013;1:32.
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
Min-Hee Ryu, Changhoon Yoo, Jong Gwang Kim, Baek-Yeol Ryoo, Young Soo Park, Sook Ryun Park, Hye-Suk Han, Ik Joo Chung, Eun-Kee Song, Kyung Hee Lee, Seok Yun Kang, Yoon-Koo Kang
European Journal of Cancer, Volume 51, Issue 4, March 2015, Pages 482 - 488